ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice

Vaccine

Volumn 35, Issue 30, 2017, Pages 3780-3788

  Alharbi, Naif Khalaf ^a,b   Padron Regalado, Eriko ^a   Thompson, Craig P ^a   Kupke, Alexandra ^c,d   Wells, Daniel ^a   Sloan, Megan A ^a   Grehan, Keith ^e   Temperton, Nigel ^e   Lambe, Teresa ^a   Warimwe, George ^a   Becker, Stephan ^c,d   Hill, Adrian V S ^a   Gilbert, Sarah C ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d German Center for Infection Research   (Germany)

^e UNIVERSITY OF KENT   (United Kingdom)

Author keywords

Adenoviral vector; ChAdOx1; Coronavirus; Immunogenicity; MERS CoV; MVA; Poxviral vector; Prime boost; Vaccination; Vaccine

Indexed keywords

CHADOX1 MERS VACCINE; MVA MERS VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS VACCINE; VIRUS VECTOR; CORONAVIRUS SPIKE GLYCOPROTEIN; MVA VACCINE; RECOMBINANT VACCINE; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; IMMUNOGENICITY; MIDDLE EAST RESPIRATORY SYNDROME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TPA GENE; TRANSGENE; VACCINATION; VIRUS NEUTRALIZATION; VIRUS PARTICLE; VIRUS TRANSMISSION; ADENOVIRIDAE; ANIMAL; BIOSYNTHESIS; CORONAVIRUS INFECTION; DOSE RESPONSE; GENETICS; HUMORAL IMMUNITY; IMMUNOLOGY; VACCINE IMMUNOGENICITY;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CORONAVIRUS INFECTIONS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOGENICITY, VACCINE; MICE; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; SPIKE GLYCOPROTEIN, CORONAVIRUS; VACCINATION; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 85020128534     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2017.05.032     Document Type: Article

References (51)

1. Zaki, A.M., van Boheemen, S., Bestebroer, T.M., Osterhaus, A.D., Fouchier, R.A., Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. New Engl J Med 367:19 (2012), 1814–1820.
2. World Health Organisation. Middle East respiratory syndrome coronavirus (MERS-CoV) 2016. Available from: http://www.who.int/emergencies/mers-cov/en/ [accessed 20.02.2017].
3. Lessler, J., Salje, H., Van Kerkhove, M.D., Ferguson, N.M., Cauchemez, S., Rodriquez-Barraquer, I., et al. Estimating the severity and subclinical burden of Middle East respiratory syndrome coronavirus infection in the Kingdom of Saudi Arabia. Am J Epidemiol 183:7 (2016), 657–663.
4. Al Hammadi, Z.M., Chu, D.K., Eltahir, Y.M., Al Hosani, F., Al Mulla, M., Tarnini, W., et al. Asymptomatic MERS-CoV infection in humans possibly linked to infected dromedaries imported from Oman to United Arab Emirates, May 2015. Emerg Infect Dis 21:12 (2015), 2197–2200.
5. Oboho, I.K., Tomczyk, S.M., Al-Asmari, A.M., Banjar, A.A., Al-Mugti, H., Aloraini, M.S., et al. 2014 MERS-CoV outbreak in Jeddah–a link to health care facilities. N Engl J Med 372:9 (2015), 846–854.
6. Who Mers-Cov Research G. State of knowledge and data gaps of Middle East respiratory syndrome coronavirus (MERS-CoV) in humans. PLoS Curr 2013;5.
7. Memish, Z.A., Zumla, A.I., Assiri, A., Middle East respiratory syndrome coronavirus infections in health care workers. New Engl J Med 369:9 (2013), 884–886.
8. Muller, M.A., Corman, V.M., Jores, J., Meyer, B., Younan, M., Liljander, A., et al. MERS coronavirus neutralizing antibodies in camels, Eastern Africa, 1983–1997. Emerg Infect Dis 20:12 (2014), 2093–2095.
9. Perera RA, Wang P, Gomaa MR, El-Shesheny R, Kandeil A, Bagato O, et al. Seroepidemiology for MERS coronavirus using microneutralisation and pseudoparticle virus neutralisation assays reveal a high prevalence of antibody in dromedary camels in Egypt, June 2013. Euro surveillance: bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 2013;18(36): pii=20574.
10. Hemida, M.G., Perera, R.A., Al Jassim, R.A., Kayali, G., Siu, L.Y., Wang, P., et al. Seroepidemiology of Middle East respiratory syndrome (MERS) coronavirus in Saudi Arabia (1993) and Australia (2014) and characterisation of assay specificity. Euro Surveillance: Bull Eur sur les maladies transmissibles = Eur Commun Dis Bull, 19(23), 2014.
11. Gutierrez, C., Tejedor-Junco, M.T., Gonzalez, M., Lattwein, E., Renneker, S., Presence of antibodies but no evidence for circulation of MERS-CoV in dromedaries on the Canary Islands, 2015. Euro Surveillance: Bull Eur sur les maladies transmissibles = Eur Commun Dis Bull, 20(37), 2015.
12. Ali, M.A., Shehata, M.M., Gomaa, M.R., Kandeil, A., El-Shesheny, R., Kayed, A.S., et al. Systematic, active surveillance for Middle East respiratory syndrome coronavirus in camels in Egypt. Emerg Microbes Infect, 6(1), 2017, e1.
13. van Doremalen, N., Hijazeen, Z.S., Holloway, P., Al Omari, B., McDowell, C., Adney, D., et al. High prevalence of Middle East respiratory coronavirus in young dromedary camels in Jordan. Vector Borne Zoonotic Dis 17:2 (2017), 155–159.
14. Alraddadi, B.M., Watson, J.T., Almarashi, A., Abedi, G.R., Turkistani, A., Sadran, M., et al. Risk factors for primary Middle East respiratory syndrome coronavirus illness in humans, Saudi Arabia, 2014. Emerg Infect Dis 22:1 (2016), 49–55.
15. Gossner, C., Danielson, N., Gervelmeyer, A., Berthe, F., Faye, B., Kaasik Aaslav, K., et al. Human-dromedary camel interactions and the risk of acquiring zoonotic Middle East respiratory syndrome coronavirus infection. Zoonoses Public Health 63:1 (2016), 1–9.
16. Funk, A.L., Goutard, F.L., Miguel, E., Bourgarel, M., Chevalier, V., Faye, B., et al. MERS-CoV at the animal-human interface: inputs on exposure pathways from an expert-opinion elicitation. Front Veterin Sci, 3, 2016, 88.
17. Reusken, C.B., Ababneh, M., Raj, V.S., Meyer, B., Eljarah, A., Abutarbush, S., et al. Middle East Respiratory Syndrome coronavirus (MERS-CoV) serology in major livestock species in an affected region in Jordan, June to September 2013. Euro Surveillance: Bull Eur sur les maladies transmissibles = Eur Commun Dis Bull, 18(50), 2013, 20662.
18. Hemida, M.G., Perera, R.A., Wang, P., Alhammadi, M.A., Siu, L.Y., Li, M., et al. Middle East Respiratory Syndrome (MERS) coronavirus seroprevalence in domestic livestock in Saudi Arabia, 2010 to 2013. Euro Surveillance: Bull Eur sur les maladies transmissibles = Eur Commun Dis Bull, 18(50), 2013, 20659.
19. Alagaili, A.N., Briese, T., Mishra, N., Kapoor, V., Sameroff, S.C., Burbelo, P.D., et al. Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia. mBio 5:2 (2014), e00884–e914.
20. Reusken, C.B., Haagmans, B.L., Muller, M.A., Gutierrez, C., Godeke, G.J., Meyer, B., et al. Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. Lancet Infect Dis 13:10 (2013), 859–866.
21. Vergara-Alert, J., van den Brand, J.M., Widagdo, W., Mt, Munoz, Raj, S., Schipper, D., et al. Livestock susceptibility to Infection with Middle East respiratory syndrome coronavirus. Emerg Infect Dis 23:2 (2017), 232–240.
22. Adney, D.R., Brown, V.R., Porter, S.M., Bielefeldt-Ohmann, H., Hartwig, A.E., Bowen, R.A., Inoculation of goats, sheep, and horses with MERS-CoV does not result in productive viral shedding. Viruses, 8(8), 2016.
23. Alharbi, N.K., Vaccines against Middle East respiratory syndrome coronavirus for humans and camels. Rev Med Virol, 2016.
24. Draper, S.J., Heeney, J.L., Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol 8:1 (2010), 62–73.
25. Tao, D., Barba-Spaeth, G., Rai, U., Nussenzweig, V., Rice, C.M., Nussenzweig, R.S., Yellow fever 17D as a vaccine vector for microbial CTL epitopes: protection in a rodent malaria model. J Exp Med 201:2 (2005), 201–209.
26. Dicks, M.D., Spencer, A.J., Edwards, N.J., Wadell, G., Bojang, K., Gilbert, S.C., et al. A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PloS one, 7(7), 2012, e40385.
27. Gomez, C.E., Perdiguero, B., Garcia-Arriaza, J., Esteban, M., Clinical applications of attenuated MVA poxvirus strain. Exp Rev Vacc 12:12 (2013), 1395–1416.
28. Gilbert, S.C., Clinical development of modified vaccinia virus Ankara vaccines. Vaccine 31:39 (2013), 4241–4246.
29. Luo, M., Tao, P., Li, J., Zhou, S., Guo, D., Pan, Z., Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice. J Virol Meth 154:1–2 (2008), 121–127.
30. Wallace, A., West, K., Rothman, A.L., Ennis, F.A., Lu, S., Wang, S., Post-translational intracellular trafficking determines the type of immune response elicited by DNA vaccines expressing Gag antigen of Human Immunodeficiency Virus Type 1 (HIV-1). Hum Vaccin Immunother 9:10 (2013), 2095–2102.
31. Alharbi, N.K., Spencer, A.J., Salman, A.M., Tully, C.M., Chinnakannan, S.K., Lambe, T., et al. Enhancing cellular immunogenicity of MVA-vectored vaccines by utilizing the F11L endogenous promoter. Vaccine. 34:1 (2016), 49–55.
32. Warimwe, G.M., Gesharisha, J., Carr, B.V., Otieno, S., Otingah, K., Wright, D., et al. Chimpanzee adenovirus vaccine provides multispecies protection against rift valley fever. Sci Rep, 6, 2016, 20617.
33. Antrobus, R.D., Coughlan, L., Berthoud, T.K., Dicks, M.D., Hill, A.V., Lambe, T., et al. Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens. Mol Ther: J Am Soc Gene Ther 22:3 (2014), 668–674.
34. Cottingham, M.G., Carroll, F., Morris, S.J., Turner, A.V., Vaughan, A.M., Kapulu, M.C., et al. Preventing spontaneous genetic rearrangements in the transgene cassettes of adenovirus vectors. Biotechnol Bioeng 109:3 (2012), 719–728.
35. Sridhar, S., Reyes-Sandoval, A., Draper, S.J., Moore, A.C., Gilbert, S.C., Gao, G.P., et al. Single-dose protection against Plasmodium berghei by a simian adenovirus vector using a human cytomegalovirus promoter containing intron A. J Virol 82:8 (2008), 3822–3833.
36. Cottingham, M.G., Andersen, R.F., Spencer, A.J., Saurya, S., Furze, J., Hill, A.V., et al. Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA). PloS one, 3(2), 2008, e1638.
37. Volz, A., Kupke, A., Song, F., Jany, S., Fux, R., Shams-Eldin, H., et al. Protective efficacy of recombinant Modified Vaccinia virus Ankara (MVA) delivering Middle East Respiratory Syndrome coronavirus spike glycoprotein. J Virol, 2015.
38. Tscharke, D.C., Woo, W.P., Sakala, I.G., Sidney, J., Sette, A., Moss, D.J., et al. Poxvirus CD8+ T-cell determinants and cross-reactivity in BALB/c mice. J Virol 80:13 (2006), 6318–6323.
39. Draper, S.J., Moore, A.C., Goodman, A.L., Long, C.A., Holder, A.A., Gilbert, S.C., et al. Effective induction of high-titer antibodies by viral vector vaccines. Nat Med 14:8 (2008), 819–821.
40. Grehan, K., Ferrara, F., Temperton, N., An optimised method for the production of MERS-CoV spike expressing viral pseudotypes. MethodsX. 2 (2015), 379–384.
41. Song, F., Fux, R., Provacia, L.B., Volz, A., Eickmann, M., Becker, S., et al. Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies. J Virol 87:21 (2013), 11950–11954.
42. Muthumani, K., Falzarano, D., Reuschel, E.L., Tingey, C., Flingai, S., Villarreal, D.O., et al. A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. Sci Transl Med, 7(301), 2015, 301ra132.
43. Lan, J., Yao, Y., Deng, Y., Chen, H., Lu, G., Wang, W., et al. Recombinant receptor binding domain protein induces partial protective immunity in rhesus macaques against Middle East respiratory syndrome coronavirus challenge. EBioMedicine 2:10 (2015), 1438–1446.
44. Wang, L., Shi, W., Joyce, M.G., Modjarrad, K., Zhang, Y., Leung, K., et al. Evaluation of candidate vaccine approaches for MERS-CoV. Nat Commun, 6, 2015, 7712.
45. Haagmans, B.L., van den Brand, J.M., Raj, V.S., Volz, A., Wohlsein, P., Smits, S.L., et al. An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels. Science 351:6268 (2016), 77–81.
46. Pellerin C. Army Scientists Begin First MERS Vaccine Clinical Trial. DoD News, Defense Media Activity; 2016.
47. Warimwe, G.M., Lorenzo, G., Lopez-Gil, E., Reyes-Sandoval, A., Cottingham, M.G., Spencer, A.J., et al. Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice. Virol J, 10, 2013, 349.
48. Wang, W., Wang, H., Deng, Y., Song, T., Lan, J., Wu, G., et al. Characterization of anti-MERS-CoV antibodies against various recombinant structural antigens of MERS-CoV in an imported case in China. Emerg Microb Infect, 5(11), 2016, e113.
49. Min, C.K., Cheon, S., Ha, N.Y., Sohn, K.M., Kim, Y., Aigerim, A., et al. Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity. Sci Rep, 6, 2016, 25359.
50. Park, W.B., Perera, R.A., Choe, P.G., Lau, E.H., Choi, S.J., Chun, J.Y., et al. Kinetics of Serologic Responses to MERS Coronavirus Infection in Humans, South Korea.. Emerg Infect Dis 21:12 (2015), 2186–2189.
51. Corman, V.M., Albarrak, A.M., Omrani, A.S., Albarrak, M.M., Farah, M.E., Almasri, M., et al. Viral shedding and antibody response in 37 patients with Middle East respiratory syndrome coronavirus infection. Clin Infect Dis 62:4 (2016), 477–483.